April 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday in a class action complaint alleging it misused its patents ...

AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...

Hamburg (ots) - Mehr als drei Viertel (77 Prozent) der Frauen über 50 Jahre in Deutschland kennen den Risikofaktor höheres ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

In the latest market close, Astrazeneca (AZN) reached $64.90, with a -1.35% movement compared to the previous day. The stock's change was more than the S&P 500's daily loss of 1.57%. Elsewhere ...

NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca mit einem Kursziel von 15318 Pence auf "Buy" belassen. Die Zwischenergebnisse der Destiny-Brustkreb ...

Astrazeneca (AZN) ended the recent trading session at $72.72, demonstrating a -0.45% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss ...

Soliris (eculizumab) was first approved for paroxysmal nocturnal hemoglobinuria (PNH) in 2007 under Alexion, which later became AstraZeneca’s rare disease unit after its $39 billion buyout in 2020.

Insurer EmblemHealth is leading a class-action lawsuit against a subsidiary of AstraZeneca, claiming that the company blocked competition for a pricey, rare blood disease medication and ...

AstraZeneca PLC AZN shares slid 1.19% to £113.16 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.30% to 8,663.80 ...

AstraZeneca’s (AZN) Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with resectable non-small cell lung cancer, NSCLC, at high ...

When AstraZeneca gobbled up Alexion Pharmaceuticals in one of the biggest-ever takeovers of a Boston company, there was some hope it might mean more jobs here instead of the cuts that often follow ...